Robert Franklin

Robert Allison Franklin , MD

Assistant Professor of Clinical

University of Cincinnati Medical Center
234 Goodman St
234 Goodman St
Cincinnati, Ohio 45219
Phone 513-585-8222
Email franklro@ucmail.uc.edu

Education

Bachelor of Arts: University of Georgia Atlanta, GA, 2008 (Philosophy, English Literature)

MD: University of Tennessee Health Science Center College of Medicine Memphis, TN, 2015 (Medicine)

Residency: University of Cincinnati Medical Center Cincinnati, Ohio, 2018 (Internal Medicine)

Certifications

American Board of Internal Medicine (Certification Date: 08-24-2018 )

American Board of Internal Medicine (Hematology) (Certification Date: 11-30-2022 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-29-2022 )

Clinical Interests

Lung Cancer

Thoracic Cancer

Medical Oncology

Oncology

Bladder Cancer

Kidney Cancer

Penile Cancer

Prostate Cancer

Testicular Cancer

Hematology and Oncology

Specialities

Internal Medicine

Hematology

Medical Oncology

Research Support

Grant: #D9723C00001 Investigators:Franklin, Robert 04-08-2024 -04-08-2027 AstraZeneca Pharmaceuticals LP A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration Role:PI 0.00 Hold Level:Industry

Investigators:Franklin, Robert 04-29-2024 -05-29-2024 Myovant Sciences Relugolix Versus Leuprolide in Patients with PRostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) Role:PI 0.00 Hold Level:Industry

Investigators:Franklin, Robert 11-15-2024 -11-15-2027 ICON Clinical Research, LLC A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma Role:PI 760375.95 Hold Level:Industry

Grant: #HCRN-GU20-436 Investigators:Franklin, Robert 12-18-2024 -12-18-2027 Hoosier Cancer Research Network, Inc. HCRN-GU20-436: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alteration Role:PI 85922.50 Hold Level:Industry

Contact Information

Academic - University of Cincinnati Medical Center
234 Goodman St
CincinnatiĀ  Ohio, 45219
Phone: 513-585-8222
franklro@ucmail.uc.edu